Outcomes of fetal listed patients awaiting heart transplantation. (6th August 2013)

• Record Type: Journal Article
• Authors: Conway, Jennifer; Chrisant, Maryanne R. K.; West, Lori J.; Ameduri, Rebecca K.; Alejos, Juan C.; Lamour, Jacqueline M.; Das, Bibhuti; Gilbert, Deborah; Tresler, Margaret; Naftel, David C.; Miyamoto, Shelley D.
• Is Part Of: Pediatric transplantation. Volume 17:Number 7(2013:Nov.)
• Page Start: 653
• Page End: 660
• Publication Date: 2013-08-06
• Subjects: Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.12130
• Languages: English
• ISSNs: 1397-3142

Abstract

<abstract abstract-type="main" id="petr12130-abs-0001"> <title>Abstract</title> <p>HTx in neonates is mainstay therapy for those with severe cardiomyopathies and congenital heart disease. Fetal listing for HTx has been proposed as a way to increase the potential window for a donor with outcomes predicted to be similar to the neonatal population. Data from the PHTS, a prospective multicenter study, were used to examine the outcomes of fetuses listed between 1993 and 2009. Four thousand three hundred and sixty‐five children were listed for HTx during this period. Fetuses comprised 1% and neonates 19.8% of listed patients. In those patients listed as fetus and transplanted, the median wait time from listing to HTx was 55 days (range 4–255), with a median of 25 days (range 0–233) after birth. By six months post‐listing, a higher proportion of fetal listed patients had undergone HTx with a lower waitlist mortality when compared with neonate. There was no significant difference in survival following HTx between the two group (p = 0.4). While the results of this study may be less applicable to current practice due to changes in referrals for fetal listing, they do indicate that fetal listing can be a reasonable option. These results are of particular interest at the present time given the ongoing public discourse on the proposed elimination of fetal listing within UNOS.</p> </abstract>